Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area
appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and …

Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …

Background: Epicardial adipose tissue (EAT) accumulation is thought to play a role in the
pathophysiology of heart failure (HF) with mid-range and preserved ejection fraction, but its …

Obesity contributes to reduced life expectancy because of its link with type 2 diabetes and
cardiovascular disease. Yet, targeting this poorly diagnosed, ill-defined, and …

Background Obesity has increased in recent years with consequences on diabetes and
other comorbidities. Thus, 1 out of 3 diabetic patients suffers cardiovascular disease (CVD) …

Cardiovascular (CV) disease and heart failure (HF) are the leading cause of mortality in type
2 diabetes (T2DM), a metabolic disease which represents a fast-growing health challenge …

Background HIV-associated lipohypertrophy, which is characterised by an abnormal
accumulation of abdominal visceral adipose tissue, remains problematic in people with HIV …

Aims Human epicardial adipose tissue (EAT) plays a crucial role in the development and
progression of coronary artery disease, atrial fibrillation, and heart failure. Microscopically …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce body
weight in overweight or people with obesity and to improve glycemic control and …